Cytokinetics Inc. About
Cytokinetics Inc: Cytokinetics, Inc. (Nasdaq: CYTK) is
a leading biopharmaceutical company focused on the discovery, development and
commercialization of novel small molecule drugs that specifically target the
cytoskeleton.
A number of commonly used drugs and a growing body of research validate the role
that the cytoskeleton plays in a wide array of human diseases. Cytokinetics focus
on the cytoskeleton enables them to develop novel and potentially safer and more
effective classes of drugs directed at treatments for cancer, cardiovascular disease,
fungal diseases and other diseases. Cytokinetics has two drug candidates
for the treatment of cancer, a drug candidate for the treatment of acute congestive
heart failure and more than ten other research programs. Their most advanced drug
candidate is SB-715992. Cytokinetics' second KSP inhibitor is SB-743921.
Product
Pipeline Data for Cytokinetics Oncology Program:
SB-715992 for: Monotherapy -- Leukemia, solid tumors, non-small cell lung cancer,
breast, ovarian, colorectal, prostate, head and neck, and melanoma. More
on Cytokinetics:
Key
Statistics for Cytokinetics
Basic
Chart for Cytokinetics